Changshan pharmaceutical sodium hyaluronate has completed clinical trials

Zhang Wei, financial director and Secretary of Changshan pharmaceutical industry, said in a conference call that at present, the main construction of the company's sodium hyaluronate new car room has been completed, and the equipment bidding has been completed It is expected that all of them will be completed by the end of the year, at which time, the injection level production approval documents will be applied Changshan pharmaceutical's annual report of 2013 also shows that the medium and small molecular sodium hyaluronate, which is mainly used for the treatment of intestinal adhesion and osteoarthritis, has completed clinical trials and will be declared soon The company plans to take medical injection as the goal, strengthen the R & D investment, and strive to make hyaluronic acid another pillar product of the company Zhang Wei had previously predicted that the pharmaceutical grade sodium hyaluronate would not be available until 2015 at the earliest In fact, the sodium hyaluronate of Changshan pharmaceutical industry has been produced for many years, mainly at the level of cosmetics, with a relatively small output After the above new workshop is put into production, it will be able to achieve a capacity of about 20 tons Zhang Wei said that the company is currently doing Market Research on sodium hyaluronate, "this product is ready, and it will be larger than heparin sodium API Market in the future." According to Hongyuan Securities Research Report, Shandong furida is the main manufacturer of hyaluronic acid in China, and its raw materials of hyaluronic acid are mainly divided into injection grade, eye drop grade, beauty grade, food grade, etc Among them, beauty grade is the main source of the company's income, accounting for more than 50%, and maintaining more than 20% growth, followed by medical grade eye drops and injection, with a compound growth rate of 43.92% and 28.40% respectively in the past five years.